References: Tips for Managing Multiple Medication Use

April 17, 2024

Publication

Article

SvyatoslavBalan/AdobeStock

Below is the reference list for the article, "Tips for Managing Multiple Medication Use," by Sheldon Preskorn, MD, featured in the Special Report on Polypharmacy in Psychiatric Times, Vol. 41, Issue 15.

References

1. Preskorn SH. Do you feel lucky? J Pract Psychiatry Behav Health. 1998;4(1):37-40.

2. Preskorn SH. How multiple medication use evolves and the importance of therapeutic trials: the slippery slide. J Psychiatr Pract. 2008;14(3):170-175.

3. Preskorn SH, Silkey B. Multiple medications, multiple considerations. J Psychiatr Pract. 2001;7(1):48-52.

4. Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the Veterans Affairs healthcare system: part I: outpatient use in relation to age and number of prescribers. J Psychiatr Pract. 2005;11(1):5-15.

5. Silkey B, Preskorn SH, Golbeck A, et al. Complexity of medication use in the Veterans Affairs healthcare system: part II: antidepressant use among younger and older outpatients. J Psychiatr Pract. 2005;11(1):16-26.

6. Preskorn SH. The essential parallels between clinical practice and the scientific method. J Psychiatr Pract. 2024;30(1):43-45.

7. McMahon D, Preskorn SH. The package insert: who writes it and why, what are its implications, and how well does medical school explain it? J Psychiatr Pract. 2014;20(4):284-290.

8. Preskorn SH. Clinical psychopharmacology and medical malpractice: the four Ds. J Psychiatr Pract. 2014;20(5):363-368.

9. Preskorn SH, Lacey RL. Polypharmacy: when is it rational? J Psychiatr Pract. 2007;13(2):97-105.

10. Preskorn SH. Charting and handling genetic test results: how they differ from most laboratory results. J Psychiatr Pract. 2021;27(3):194-198.

11. Preskorn SH. Charting and handling therapeutic drug monitoring results: how they differ from most laboratory results. J Psychiatr Pract. 2021;27(4):283-287.

Further Reading

Brunton LL, Knollmann BC, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2022.

McKay GA, Walters MR, Ritchie ND, eds. Clinical Pharmacology and Therapeutics. 10th ed. Wiley-Blackwell; 2021.

Preskorn SH. Drug-drug interactions in psychiatric practice, part 1: reasons, importance, and strategies to avoid and recognize them. J Psychiatr Pract. 2018;24(4):261-268.

Preskorn SH. Drug-drug interactions (DDIs) in psychiatric practice, part 2: strategies to minimize adverse outcomes from unintended DDIs. J Psychiatr Pract. 2018;24(5):341-347.

Preskorn SH. Drug-drug interactions (DDIs) in psychiatric practice, part 3: pharmacokinetic considerations. J Psychiatr Pract. 2019;25(1):34-40.

Preskorn SH, Germann A. Drug-drug interactions in psychiatric practice, part 4: classification of neuropsychiatric medications based on their principal mechanisms of action (with updated neuroscience-based nomenclature). J Psychiatr Pract. 2019;25(2):118-127.

Preskorn SH, Germann A. Drug-drug interactions (DDIs) in psychiatric practice, part 5: major types of pharmacodynamic DDIs based on mechanism of action (with updated neuroscience-based nomenclature). J Psychiatr Pract. 2019;25(3):206-211.

Preskorn SH. Drug-drug interactions (DDIs) in psychiatric practice, part 6: pharmacodynamic considerations. J Psychiatr Pract. 2019;25(4):290-297.

Preskorn SH. Drug-drug interactions (DDIs) in psychiatric practice, part 7: relative receptor binding affinity as a way of understanding the differential pharmacology of currently available antipsychotics. J Psychiatr Pract. 2019;25(6):461-465.

Preskorn SH. Drug-drug interactions (DDIs) in psychiatric practice, part 8: relative receptor binding affinity as a way of understanding the differential pharmacology of currently available antidepressants. J Psychiatr Pract. 2020;26(1):46-51.

Preskorn SH. Drug-drug interactions (DDIs) in psychiatric practice, part 9: interactions mediated by drug-metabolizing cytochrome P450 enzymes. J Psychiatr Pract. 2020;26(2):126-134.

Preskorn SH. Drug-drug interactions: proof of relevance (part I). J Psychiatr Pract. 2005;11(2):116-122.

Preskorn SH. Drug-drug interactions: proof of relevance (part II): cause of tolerability problems or noncompliance. J Psychiatr Pract. 2005;11(6):397-401.

Preskorn SH, Kane CP, Lobello K, et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry. 2013;74(6):614-621.

Preskorn SH, Khan AY. Rational use of multiple medications in medicine and psychiatry: a dimensional perspective. J Psychiatr Pract. 2013;19(1):54-61.